Massoud Ahmed M A, El-Kholy Naglaa M B, El-Shennawy Farha A, Farag Raghda E
Department of Tropical Medicine, Faculty of Medicine for Boys, Al-Azhar University, Nast City, Cairo, Egypt.
J Egypt Soc Parasitol. 2004 Apr;34(1):315-32.
This study was planned to evaluate the in vitro production of IL-1 beta and IL-4 by peripheral blood mononuclear cells (PBMCs) and total IgE in patients with fascioliasis before and 3 months after treatment with purified extract of myrrh from Commiphora molmol tree (Mirazid), to determine the role of these variables in immunopathogenesis of the disease in relation to this new drug. The study was carried out in Departments of Tropical Medicine, Al-Azhar University Hospitals in the period from March 2002 to November 2003. A total of 35 patients with chronic fascioliasis with age range from 9-45 years in addition to 10 healthy subjects with matched age and sex serving as controls were studied. Serum IgE and in vitro IL-1 and IL-4 were estimated by enzyme immuno-assay (ELISA) before and 3 months after therapy. Results revealed significant increase in IL-1 beta in patients before treatment than control (p<0.001) but it decreased significantly after therapy (p<0.001) to reach the control level (p=0.16). In contrast, IL-4 was significantly lower than control before therapy (p=0.04) and increased significantly after treatment (p<0.001) to reach normal levels as control (p=0.59). Total IgE was significantly elevated in patients before treatment (p<0.001) and it did decrease significantly with treatment (p<0.001), although it remained significantly higher than the control level. In conclusion, Mirazid is an effective fasciolicidal drug. IL-1 may be involved in disease immunopathogenesis and the depressed IL-4 may be a phenomenon of parasite immune suppression. Complete decline of total IgE is not an early criterion of cure.
本研究旨在评估在使用没药树(Commiphora molmol)的没药纯化提取物(Mirazid)治疗前及治疗3个月后,肝片吸虫病患者外周血单个核细胞(PBMCs)产生白细胞介素-1β(IL-1β)和白细胞介素-4(IL-4)的体外情况以及总IgE水平,以确定这些变量在与这种新药相关的疾病免疫发病机制中的作用。该研究于2002年3月至2003年11月在爱资哈尔大学医院热带医学科进行。共研究了35例年龄在9至45岁的慢性肝片吸虫病患者,另外选取10名年龄和性别匹配的健康受试者作为对照。在治疗前及治疗3个月后,通过酶免疫测定法(ELISA)评估血清IgE以及体外IL-1和IL-4水平。结果显示,治疗前患者的IL-1β水平显著高于对照组(p<0.001),但治疗后显著降低(p<0.001),降至对照组水平(p=0.16)。相比之下,治疗前IL-4水平显著低于对照组(p=0.04),治疗后显著升高(p<0.001),达到与对照组相当的正常水平(p=0.59)。治疗前患者的总IgE显著升高(p<0.001),治疗后虽有显著下降(p<0.001),但仍显著高于对照组水平。总之,Mirazid是一种有效的杀肝片吸虫药物。IL-1可能参与疾病的免疫发病机制,而IL-4降低可能是寄生虫免疫抑制现象。总IgE完全下降并非治愈的早期标准。